Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tricida, Inc. (TCDAQ : OTC)

• Company Description    Tricida, Inc. is a late-stage pharmaceutical company. It focuses on the discovery and clinical development of novel therapeutics to address renal, metabolic and cardiovascular diseases. The company's product candidate consists of TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. Tricida, Inc. is based in CA, United States. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $ Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $0.26 52 Week Low: $0.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7000 SHORELINE COURT SUITE 201 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-429-7800 fax: - ir@tricida.com http://www.tricida.com

• General Corporate Information    Officers Gerrit Klaerner - Chief Executive Officer; President and Director Klaus Veitinger - Chairman of the Board of Directors Geoffrey M. Parker - Chief Operating Officer; Chief Financial Officer Annie Yoshiyama - Vice President of Finance and Chief Accounting O Robert J. Alpern - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 89610F101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: % Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©